| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
Statements of interest
The following authors have declared a statement of interest concerning papers published in volume 30 of the ERJ.
Statements of interest from previous volumes may be viewed here: volume 29.
A
Back to Top
A. Anzueto does not have a financial relationship with a commercial entity that has an interest in the subject of his manuscript. He has participated as a speaker in scientific meetings or courses organised and financed by various pharmaceutical companies including: Boehringer Ingelheim, Bayer Pharma, Pfizer, GlaxoSmithKline, Wyeth Sanofi-Aventis and Altana. He has also beeen a consultant for Boehringer Ingelheim, Abbott Laboratories, Bayer Pharma, Pfizer, GlaxoSmithKliune, Wyeth Sanofi-Aventis and Altana. He has been the principal investigator for research grants and the University of Texas Health Science Center at San Antonio was paid for participating in multicentre clinical trials sponsored by Boehringer Ingelheim, Bayer Pharma, BARS, Lilly and the National Institutes of Health. DOI: 10.1183/09031936.00071607
H.G.M. Arets. The author has received, within the last 5 yrs, €1,000 from Chiron, €200 from MSD and €500 from Ivax Pharma for lectures. DOI: 10.1183/09031936.00051406
B
Back to Top
A. Baeza-Squiban. PM2.5 and PM organic extracts in the author’s study were supplied and chemically analysed by Renault (DIMAT). DOI: 10.1183/09031936.00085907
B. Balbi's attendance at the 2006 ERS Congress was funded by Pfizer. The author also received funds as a member of staff, fees for speaking and funds for research. DOI: 10.1183/09031936.00112306
N.C. Barnes. The author’s study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
M. Barron. The RIETE Registry was supported by an unrestricted educational grant from Sanofi-Aventis Spain. The Registry Coordinating Center, S&H Medical Science Service, provided logistic and administrative support. DOI: 10.1183/09031936.00071007
E. Bathoorn has received sponsorship for attending symposia. The author also received an unrestricted grant from AstraZeneca (the Netherlands) for salary support. DOI: 10.1183/09031936.00163206
S. Bell. Pfizer contributed some unencumbered funding to reduce some of the costs of the author’s study. Pfizer supplied azithromycin for the author’s study. Funding sources did not participate in the design or conduct of this study, data analysis, manuscript preparation or review. DOI: 10.1183/09031936.00163306
I.S.T. Bos. The author’s study was supported by a grant from Boehringer Ingelheim. DOI: 10.1183/09031936.00004907
G.H. Bothamley has been employed by the UK NHS. DOI: 10.1183/09031936.00034007
J. Bourbeau. The author’s study was funded by AstraZeneca Canada Inc. DOI: 10.1183/09031936.00166606
S. Bowler. Pfizer contributed some unencumbered funding to reduce some of the costs of the author’s study. Pfizer supplied azithromycin for the author’s study. Funding sources did not participate in the design or conduct of this study, data analysis, manuscript preparation or review. DOI: 10.1183/09031936.00163306
H.C. Bucher. The author’s study was supported financially by a grant from Boehringer-Ingelheim GmbH, Basel, Switzerland. DOI: 10.1183/09031936.00015307
P. Bulpa has received fees for speaking from Pfizer, MSD and Zeneus Pharma. DOI: 10.1183/09031936.00062206
C
Back to Top
L. Caballero. The author’s study was partially supported by an unrestricted research grant from Actelion Pharmaceuticals Ltd. DOI: 10.1183/09031936.00092306
J. Carlsen. The author has been on the Actelion Tracleer PMS committee, but has not received any funding in this capacity. DOI: 10.1183/09031936.00138706
P.A. Cattini. Funding support for the research described in the author’s study was obtained from the Philip Morris External Research Program. DOI: 10.1183/09031936.00141805
A. Cayuela. The RIETE Registry was supported by an unrestricted educational grant from Sanofi-Aventis Spain. The Registry Coordinating Center, S&H Medical Science Service, provided logistic and administrative support. DOI: 10.1183/09031936.00071007
Z-Q. Cheng. Funding support for the research described in the author’s study was obtained from the Philip Morris External Research Program. DOI: 10.1183/09031936.00141805
M.P. Chung In addition to the Korea Health 21 Research and Development Project, the author’s study was also supported by a Samsung Biomedical Research Institute (Seoul, Korea) grant, number SBRI C-A6-402-1. DOI: 10.1183/09031936.00039507
P.N. Chhajed. The author’s study was supported financially by a grant from Boehringer-Ingelheim GmbH, Basel, Switzerland. DOI: 10.1183/09031936.00015307
D
Back to Top
C.W.H. Davies has been reimbursed for attending a working party group organised and paid for by LEO Pharma, the manufacturer of Innohep (tinzaparin), and for presenting this study to employees of LEO Pharma. The author’s study was supported by a research grant from LEO Pharma to pH Associates to conduct the project. pH Associates were involved in the design of the author’s study and provided assistance with data collation and reporting. DOI: 10.1183/09031936.00140506
J.C. de Jongste has, in the past 5 years, received travel grants and lectured on request at scientific meetings for GlaxoSmithKline, AstraZeneca, Merck, Sharp & Dohme, Altana Pharma, Chiron, Aerocrine and Roche. The author has also acted as scientific advisor for Aerocrine. Payments for these services went to the Dept of Pediatrics, Erasmus Medical Center Holding. The Dept of Pediatrics, Erasmus MC Holding, received research grants from GlaxoSmithKline, AstraZeneca, Aerocrine, Roche, Friesland Nutrition, Transave, Chiron and Pfizer. Medication for the author’s study was donated by GlaxoSmithKline. Representatives of the company reviewed and commented on the protocol but made no other contributions to its design, conduct, interpretation or presentation. DOI: 10.1183/09031936.00111806
P.N.R. Dekhuijzen. An unrestricted educational grant for the author’s study was received from GlaxoSmithKline (Zeist, The Netherlands). DOI: 10.1183/09031936.00125106
G.C. Donaldson. The author’s study was funded by Boehringer-Ingelheim Ltd. DOI: 10.1183/09031936.00023907
H. Dressel has received two sensors for FeNO measurements for another study from Aerocrine. DOI: 10.1183/09031936.00023807
E.J. Duiverman has, in the past 5 years, received lecture fees and travel grants from AstraZeneca, GlaxoSmithKline, MSD, Altana Pharma, Chiron and UCB Pharma. The author was also a member of an MSD medical advisory board. The Dept of Paediatric Respiratory Diseases, University Medical Center Groningen, has received research grants from Numico Research, GlaxoSmithKline, MSD and UCB Pharma. Medication for the author’s study was donated by GlaxoSmithKline. Representatives of the company reviewed and commented on the protocol but made no other contributions to its design, conduct, interpretation or presentation. DOI: 10.1183/09031936.00111806
E
Back to Top
O. Eickmeier. The author’s study was supported by a research grant from Merck Sharpe and Dohme. DOI: 10.1183/09031936.00063106
F
Back to Top
L.M. Fabbri reports having served as a consultant to Altana Pharma, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Roche and Pfizer. The author has been paid lecture fees by Altana Pharma, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Roche and Pfizer. L.M. Fabbri has also received grant support from Altana Pharma, AstraZeneca, Boehringer Ingelheim, Menarini, Miat, Schering Plough, Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp & Dohme, UCB, Pfizer, the Italian Ministry of Health, and the Italian Ministry for University and Research. DOI: 10.1183/09031936.00067307
G. Ford. The author’s study was funded by AstraZeneca Canada Inc. DOI: 10.1183/09031936.00166606
G. Freudenberg received reimbursement for attending a symposium and fees for speaking. Speeches on sleep-disordered breathing and mechanical ventilation were funded by ResMed, Airproducts and Heinen + Löwenstein. DOI: 10.1183/09031936.00073407
G
Back to Top
E. Gamble. The author’s study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
B. Gaston holds shares in Respiratory Research, Inc., a company involved in studying airway acid base chemistry. DOI: 10.1183/09031936.00015507
J.P. Gawaziuk. Funding support for the research described in the author’s study was obtained from the Philip Morris External Research Program. DOI: 10.1183/09031936.00141805
M.C.P. Geraedts. An unrestricted educational grant for the author’s study was received from GlaxoSmithKline (Zeist, The Netherlands). DOI: 10.1183/09031936.00125106
R. Gosens has received a lecture fee of €1,000 from Boehringer Ingelheim. The author’s study was supported by a grant from Boehringer Ingelheim. DOI: 10.1183/09031936.00004907
R. Gosselink. The Erasmus MC, Sophia Children’s Hospital (the cystic fibrosis centre used in the author’s study) has received, in the last 5 years, research grants from Hoffman-La-Roche. The author’s study was supported by Roche (the Netherlands); support with nebulisers was provided by Romedic (Meerssen, the Netherland); and support with pulsoxymeters was provided by MTT (Wageningen, the Netherlands). DOI: 10.1183/09031936.00031107
E.S. Green has received financial support from LEO Pharma to attend educational meetings. The author’s study was supported by a research grant from LEO Pharma to pH Associates to conduct the project. pH Associates were involved in the design of the author’s study and provided assistance with data collation and reporting. DOI: 10.1183/09031936.00140506
D.C. Grootendorst. The author’s study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
C. Gysin. The author’s study was supported financially by a grant from Boehringer-Ingelheim GmbH, Basel, Switzerland. DOI: 10.1183/09031936.00015307
H
Back to Top
M.P. Habib has received pharmaceutical grant support from Boehringer Ingelheim, Ortho McNeil, Pfizer, Bayer, Bristol-Meyers-Squibb, GlaxoSmithKline and Altana. He has also received honoraria for lectures from Daiichi Pharmaceuticals, Ortho McNeil, Pfizer and Bristol-Meyers-Squibb. DOI: 10.1183/09031936.00104606
T. Hafmans. An unrestricted educational grant for the author’s study was received from GlaxoSmithKline (Zeist, The Netherlands). DOI: 10.1183/09031936.00125106
M. Halank has received speaker's honoraria from Actelion Pharmaceuticals and Schering. DOI: 10.1183/09031936.00032407
A.J. Halayko. The author’s study was supported by a grant from Boehringer Ingelheim. DOI: 10.1183/09031936.00004907
P.C. Hallal. The PLATINO study was funded by Boehringer Ingelheim GmbH (Ingelheim, Germany). The funding source had no influence on the analyses or interpretation of the results presented in the paper. The corresponding author (A.M.B. Menezes) had full access to all the data in the study and had final responsibility for the decision to submit for publication. DOI: 10.1183/09031936.00083507
R. Hamel. PM2.5 and PM organic extracts in the author’s study were supplied and chemically analysed by Renault (DIMAT). DOI: 10.1183/09031936.00085907
M. Harris. Pfizer contributed some unencumbered funding to reduce some of the costs of the author’s study. Pfizer supplied azithromycin for the author’s study. Funding sources did not participate in the design or conduct of this study, data analysis, manuscript preparation or review. DOI: 10.1183/09031936.00163306
K. Hattotuwa. The author’s study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
L.M.A. Heunks. An unrestricted educational grant for the author’s study was received from GlaxoSmithKline (Zeist, The Netherlands). DOI: 10.1183/09031936.00125106
G. Hoeffken has received speaker's honoraria from Actelion Pharmaceuticals and Schering. DOI: 10.1183/09031936.00032407
M.M. Hoeper. The author is a member of Actelion’s International Scientific Advisory Board and has received honoraria for speaking at conferences from Actelion Pharmaceuticals. The author has also received reimbursements for attending symposia and funds for research. DOI: 10.1183/09031936.00138706
M.M. Hoeper has received speaker's honoraria from Actelion Pharmaceuticals and Schering, and has served as an advisory board member for Actelion Pharmaceuticals. DOI: 10.1183/09031936.00032407
W.C.J. Hop’s department provides regular statistical consultancies to GlaxoSmithKline. Medication for the author’s study was donated by GlaxoSmithKline. Representatives of the company reviewed and commented on the protocol but made no other contributions to its design, conduct, interpretation or presentation. DOI: 10.1183/09031936.00111806
W.C.J. Hop. The Erasmus MC, Sophia Children’s Hospital (the cystic fibrosis centre used in the author’s study) has received, in the last 5 years, research grants from Hoffman-La-Roche. The author’s study was supported by Roche (the Netherlands); support with nebulisers was provided by Romedic (Meerssen, the Netherland); and support with pulsoxymeters was provided by MTT (Wageningen, the Netherlands). DOI: 10.1183/09031936.00031107
D. Horstkotte is a staff member funded by ResMed. DOI: 10.1183/09031936.00073407
M. Humbert has relationships with drug companies that include Actelion, Encysive, GlaxoSmithKline, Myogen, Schering, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, M. Humbert’s other relationships with these companies include consultancy services and membership of scientific advisory boards. DOI: 10.1183/09031936.00055407
M. Humbert. The author has relationships with drug companies including Actelion, GlaxoSmithKline, Schering, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy services and membership of scientific advisory boards. DOI: 10.1183/09031936.00138706
J.F. Hunt has received funds for research. In the past 5 years, the author has been employed by and is a founder of Respiratory Research, Inc. He also holds stocks or shares in this company, which has an interest in airway pH, and has provided funds for his laboratory. J.F. Hunt owns intellectual property in methodology relevant to therapeutic airway alkalinisation. DOI: 10.1183/09031936.00015507
I
Back to Top
J
Back to Top
L.J. Janssen. The author’s study was supported by a grant-in-aid provided by AstraZeneca International. DOI: 10.1183/09031936.00025907
J.R.B. Jardim. The PLATINO study was funded by Boehringer Ingelheim GmbH (Ingelheim, Germany). The funding source had no influence on the analyses or interpretation of the results presented in the paper. The corresponding author (A.M.B. Menezes) had full access to all the data in the study and had final responsibility for the decision to submit for publication. DOI: 10.1183/09031936.00083507
P.K. Jeffery. The author’s study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
G.J. Jenniskens. An unrestricted educational grant for the author’s study was received from GlaxoSmithKline (Zeist, The Netherlands). DOI: 10.1183/09031936.00125106
P. Jones is a consultant statistician who is contracted to Boehringer-Ingelheim (among other companies). His affiliation is shown as Boehringer-Ingelheim on the author list. The author’s study was funded by Boehringer-Ingelheim Ltd. DOI: 10.1183/09031936.00023907
K
Back to Top
F. Kauffmann. The author received a grant of €720,000 from Merck, Sharp and Dohme in 2002 for the follow-up and genetic studies of the EGEA cohort (not including the present genome screen). DOI: 10.1183/09031936.00162206
H.A.M. Kerstjens has received sponsorship from AstraZeneca to travel to an ATS congress. The author has spoken at symposia organised by the company and the company also financed the study presented in the December 2007 issue of the European Respiratory Journal. The author’s institution has received an educational grant to appoint a PhD fellow (E. Bathoorn). Competing arrangements apply with the competitors GlaxoSmithKline and Altana. DOI: 10.1183/09031936.00163206
S. Kesten is a full-time employee of Boehringer-Ingelheim. The author’s study was funded by Boehringer-Ingelheim Ltd. DOI: 10.1183/09031936.00023907
S. Kesten works for Boehringer Ingelheim Corporation, Ingelheim, Germany. DOI: 10.1183/09031936.00104606
P. Kesteven. The author’s study was supported by a research grant from LEO Pharma to pH Associates to conduct the project. pH Associates were involved in the design of the author’s study and provided assistance with data collation and reporting. DOI: 10.1183/09031936.00140506
M.A. Khan. The author’s study was supported by a grant-in-aid provided by AstraZeneca International. DOI: 10.1183/09031936.00025907
S. Kianpour. The author’s study was supported by a grant-in-aid provided by AstraZeneca International. DOI: 10.1183/09031936.00025907
D.G. Kiely. The author is a member of an Advisory Board for Actelion Pharmaceuticals and Pfizer, and has received fees for giving educational lectures for Scherring, Actelion, Pfizer and United Therapeutics. The author has also received reimbursements for attending symposia, fees for speaking, funds for research, funds for a member of staff and fees for consulting. DOI: 10.1183/09031936.00138706
J. Killen. The author’s study was supported by a research grant from LEO Pharma to pH Associates to conduct the project. pH Associates were involved in the design of the author’s study and provided assistance with data collation and reporting. DOI: 10.1183/09031936.00140506
E.J. Kim. In addition to the Korea Health 21 Research and Development Project, the author’s study was also supported by a Samsung Biomedical Research Institute (Seoul, Korea) grant, number SBRI C-A6-402-1. DOI: 10.1183/09031936.00039507
H. Kim. In addition to the Korea Health 21 Research and Development Project, the author’s study was also supported by a Samsung Biomedical Research Institute (Seoul, Korea) grant, number SBRI C-A6-402-1. DOI: 10.1183/09031936.00039507
S.Y. Kim. In addition to the Korea Health 21 Research and Development Project, the author’s study was also supported by a Samsung Biomedical Research Institute (Seoul, Korea) grant, number SBRI C-A6-402-1. DOI: 10.1183/09031936.00039507
J.L.L. Kimpen received honoraria for organising educational events for Abbott International. The author has given unrestricted lectures at these educational events and was hired as a consultant by the same organisation. DOI: 10.1183/09031936.00031407
R. Kitz. The author’s study was supported by a research grant from Merck Sharpe and Dohme. DOI: 10.1183/09031936.00063106
W-J. Koh. In addition to the Korea Health 21 Research and Development Project, the author’s study was also supported by a Samsung Biomedical Research Institute (Seoul, Korea) grant, number SBRI C-A6-402-1. DOI: 10.1183/09031936.00039507
A. Kotaniemi-Syrjänen. An unrestricted grant was received from Merck Sharp & Dohme Ltd for the author’s study. DOI: 10.1183/09031936.00158106
C. Kroegel. The author’s study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
O.J. Kwon. In addition to the Korea Health 21 Research and Development Project, the author’s study was also supported by a Samsung Biomedical Research Institute (Seoul, Korea) grant, number SBRI C-A6-402-1. DOI: 10.1183/09031936.00039507
L
Back to Top
B. Lamp received fees for speaking, for organising education and for consulting from ResMed. The author also acted as an expert witness on the subject of the printed letter. DOI: 10.1183/09031936.00073407
J. Lee. The author’s study was funded by AstraZeneca Canada Inc. DOI: 10.1183/09031936.00166606
S-H. Lee. In addition to the Korea Health 21 Research and Development Project, the author’s study was also supported by a Samsung Biomedical Research Institute (Seoul, Korea) grant, number SBRI C-A6-402-1. DOI: 10.1183/09031936.00039507
J.D. Leuppi. The author’s study was supported financially by a grant from Boehringer-Ingelheim GmbH, Basel, Switzerland. DOI: 10.1183/09031936.00015307
B.D. Levy has received patent licensing fees from Berlex-Schering AG. DOI: 10.1183/09031936.00005807
M.V. Lopez. The PLATINO study was funded by Boehringer Ingelheim GmbH (Ingelheim, Germany). The funding source had no influence on the analyses or interpretation of the results presented in the paper. The corresponding author (A.M.B. Menezes) had full access to all the data in the study and had final responsibility for the decision to submit for publication. DOI: 10.1183/09031936.00083507
M
Back to Top
X. Ma. Funding support for the research described in the author’s study was obtained from the Philip Morris External Research Program. DOI: 10.1183/09031936.00141805
M.J. Mäkelä. An unrestricted grant was received from Merck Sharp & Dohme Ltd for the author’s study. DOI: 10.1183/09031936.00158106
A. Malhotra. The author has relationships with a number of companies for research grants (Respironics, Restore Medical), consulting (Inspiration Medical, Restore Medical) and speakers’ bureaus (Sepracor, Respironics). DOI: 10.1183/09031936.00063406
L.P. Malmberg. An unrestricted grant was received from Merck Sharp & Dohme Ltd for the author’s study. DOI: 10.1183/09031936.00158106
K. Malmström. An unrestricted grant was received from Merck Sharp & Dohme Ltd for the author’s study. DOI: 10.1183/09031936.00158106
F. Marano. PM2.5 and PM organic extracts in the author’s study were supplied and chemically analysed by Renault (DIMAT). DOI: 10.1183/09031936.00085907
J.J. Martín. The RIETE Registry was supported by an unrestricted educational grant from Sanofi-Aventis Spain. The Registry Coordinating Center, S&H Medical Science Service, provided logistic and administrative support. DOI: 10.1183/09031936.00071007
J. McCormack. Pfizer contributed some unencumbered funding to reduce some of the costs of the author’s study. Pfizer supplied azithromycin for the author’s study. Funding sources did not participate in the design or conduct of this study, data analysis, manuscript preparation or review. DOI: 10.1183/09031936.00163306
J.J.V. McMurray. The author’s study was partially supported by an unrestricted research grant from Actelion Pharmaceuticals Ltd. DOI: 10.1183/09031936.00092306
I. Mehdi. The author’s study was supported by a research grant from LEO Pharma to pH Associates to conduct the project. pH Associates were involved in the design of the author’s study and provided assistance with data collation and reporting. DOI: 10.1183/09031936.00140506
A.M.B. Menezes. The PLATINO study was funded by Boehringer Ingelheim GmbH (Ingelheim, Germany). The funding source had no influence on the analyses or interpretation of the results presented in the paper. A.M.B. Menezes had full access to all the data in the study and had final responsibility for the decision to submit for publication. DOI: 10.1183/09031936.00083507
H. Meurs. The author’s study was supported by a grant from Boehringer Ingelheim. DOI: 10.1183/09031936.00004907
G. Michaud has received an honorarium from Denver Biomedical for a continuing medical education seminar to discuss the role of Pleurx catheters in malignant pleural effusion. DOI: 10.1183/09031936.00164706
D. Miedinger. The author’s study was supported financially by a grant from Boehringer-Ingelheim GmbH, Basel, Switzerland. DOI: 10.1183/09031936.00015307
M. Monreal. The RIETE Registry was supported by an unrestricted educational grant from Sanofi-Aventis Spain. The Registry Coordinating Center, S&H Medical Science Service, provided logistic and administrative support. DOI: 10.1183/09031936.00071007
M. Montes de Oca. The PLATINO study was funded by Boehringer Ingelheim GmbH (Ingelheim, Germany). The funding source had no influence on the analyses or interpretation of the results presented in the paper. The corresponding author (A.M.B. Menezes) had full access to all the data in the study and had final responsibility for the decision to submit for publication. DOI: 10.1183/09031936.00083507
F. Morell. The author’s study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
H. Muellerova. The author is an employee of GlaxoSmithKline, in the Research and Development Dept. DOI: 10.1183/09031936.00157906
A. Muiño. The PLATINO study was funded by Boehringer Ingelheim GmbH (Ingelheim, Germany). The funding source had no influence on the analyses or interpretation of the results presented in the paper. The corresponding author (A.M.B. Menezes) had full access to all the data in the study and had final responsibility for the decision to submit for publication. DOI: 10.1183/09031936.00083507
B. Müller has served as a consultant and received payments from Brahms AG to attend meetings. The author has also received research support and fulfilled speaking engagements. DOI: 10.1183/09031936.0166106
N.F. Murphy. The author’s study was partially supported by an unrestricted research grant from Actelion Pharmaceuticals Ltd. DOI: 10.1183/09031936.00092306
N
Back to Top
D.E. Niewoehner has received research grants, consulting fees and speaking fees from Boehringer-Ingelheim, and speaking fees from Pfizer. DOI: 10.1183/09031936.00104606
E. Norrman received 49% of the costs for attending the European Respiratory Society Congress 2005 from AstraZeneca. DOI: 10.1183/09031936.00121705
M. Nuijsink was appointed as a clinical research fellow by GlaxoSmithKline and received lecture fees and travel support from that company. The author also received funds for research. Medication for the author’s study was donated by GlaxoSmithKline. Representatives of the company reviewed and commented on the protocol but made no other contributions to its design, conduct, interpretation or presentation. DOI: 10.1183/09031936.00111806
O
Back to Top
O. Oldenburg has received travel grants and a fee for speaking from ResMed. DOI: 10.1183/09031936.00073407
W. Oldfield. The author’s study was supported by a research grant from LEO Pharma to pH Associates to conduct the project. pH Associates were involved in the design of the author’s study and provided assistance with data collation and reporting. DOI: 10.1183/09031936.00140506
T. O’Shaughnessy. The author’s study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
R. Otero. The RIETE Registry was supported by an unrestricted educational grant from Sanofi-Aventis Spain. The Registry Coordinating Center, S&H Medical Science Service, provided logistic and administrative support. DOI: 10.1183/09031936.00071007
P
Back to Top
K. Patel. Pfizer contributed some unencumbered funding to reduce some of the costs of the author’s study. Pfizer supplied azithromycin for the author’s study. Funding sources did not participate in the design or conduct of this study, data analysis, manuscript preparation or review. DOI: 10.1183/09031936.00163306
I.D. Pavord. The author’s study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
A.J. Peacock received fees for consulting and support for attending symposia and congresses from Pfizer, Actelion and Encysive. The author’s study was partially supported by an unrestricted research grant from Actelion Pharmaceuticals Ltd. DOI: 10.1183/09031936.00092306
A.S. Pelkonen. An unrestricted grant was received from Merck Sharp & Dohme Ltd for the author’s study. DOI: 10.1183/09031936.00158106
K. Pendry has been reimbursed by LEO Pharma, the manufacturer of tinzaparin, for attending a conference to present a paper on this work, entitled: "Outpatient treatment of patients with pulmonary embolism: results of a two phase observational study". The author’s study (in the October issue of the ERJ) was supported by a research grant from LEO Pharma to pH Associates to conduct the project. pH Associates were involved in the design of the author’s study and provided assistance with data collation and reporting. DOI: 10.1183/09031936.00140506
R. Perez-Padilla has received fees for two conferences from GlaxoSmithKline and funding for travel to a congress. The PLATINO study was funded by Boehringer Ingelheim GmbH (Ingelheim, Germany). The funding source had no influence on the analyses or interpretation of the results presented in the paper. The corresponding author (A.M.B. Menezes) had full access to all the data in the study and had final responsibility for the decision to submit for publication. DOI: 10.1183/09031936.00083507
J. Pertuze. The PLATINO study was funded by Boehringer Ingelheim GmbH (Ingelheim, Germany). The funding source had no influence on the analyses or interpretation of the results presented in the paper. The corresponding author (A.M.B. Menezes) had full access to all the data in the study and had final responsibility for the decision to submit for publication. DOI: 10.1183/09031936.00083507
C.A. Piquette has been a member of the Boehringer-Ingelheim speakers’ bureau and has received funds to support COPD research. The author also received sponsorship for attending a symposium. DOI: 10.1183/09031936.00104606
N. Pinsky. The author’s study was funded by AstraZeneca Canada Inc. DOI: 10.1183/09031936.00166606
C. Pison. The author received grants/research support from Novartis, Encysive, GSK France, Boehringer Ingelheim France, AstraZeneca, Pfizer France, Bioproject, Astellas France, Numico and Nutricia France, Boston Scientific, LFB France and Bayer. The author has also consulted for Actélion France and Nutricia, and is a member of Speakers’ Bureau: Novartis, Actélion, Boehringer Ingelheim France, Nutricia France, LFB France. DOI: 10.1183/09031936.00162206
D.S. Postma has received: reimbursement for attending symposia from AstraZeneca, GSK and Altana; funds for research from AstraZeneca, GSK and Altana; and consultant fees from Altana and GSK. DOI: 10.1183/09031936.00163206
D.J. Powrie has received sponsorship from Boehringer-Ingelheim for travel to academic meetings. The author’s study was funded by Boehringer-Ingelheim Ltd. DOI: 10.1183/09031936.00023907
Q
Back to Top
Y. Qiu. The author’s study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
C.A.C. Ottenheijm. An unrestricted educational grant for the author’s study was received from GlaxoSmithKline (Zeist, The Netherlands). DOI: 10.1183/09031936.00125106
R
Back to Top
K.F. Rabe. The author’s study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
F.S.F. Ram. The author’s study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
K. Ramgolam. PM2.5 and PM organic extracts in the author’s study were supplied and chemically analysed by Renault (DIMAT). DOI: 10.1183/09031936.00085907
J. Rello has served as a consultant for Bard (Murray Hill, NJ, USA), Wyeth (Madison, NJ, USA) and Intrabiotics (Carlsbad, CA, USA), and has received research grants from Bard. DOI: 10.1183/09031936.00048507
A.H. Remels. The author is supported by a grant from Numico Research (Wageningen, the Netherlands). Funding sources had no involvement in the collection, analysis and interpretation of data; in the writing of the report; or the decision to submit the paper for publication. The authors would like to disclose that there are no advisory board affiliations or financial or personal interests in any organisation sponsoring the research and accept full responsibility for conduct of the study and the decision to publish the present work. DOI: 10.1183/09031936.00144106
C. Rodríguez. The RIETE Registry was supported by an unrestricted educational grant from Sanofi-Aventis Spain. The Registry Coordinating Center, S&H Medical Science Service, provided logistic and administrative support. DOI: 10.1183/09031936.00071007
M.A. Rose has, within the last 3 years, received honoraria for lectures from Merck Sharpe and Dohme. The author’s study was supported by a research grant from Merck Sharpe and Dohme. DOI: 10.1183/09031936.00063106
P. Rose has received financial support from LEO Pharma to attend educational meetings. The author’s study was supported by a research grant from LEO Pharma to pH Associates to conduct the project. pH Associates were involved in the design of the author’s study and provided assistance with data collation and reporting. DOI: 10.1183/09031936.00140506
M. Rosewich. The author’s study was supported by a research grant from Merck Sharpe and Dohme. DOI: 10.1183/09031936.00063106
B.H. Rowe has received financial support (research grants, consulting fees and lecture fees) in the past 5 years from Abbott Pharmaceuticals, AstraZeneca, GlaxoSmithKline and Wyeth Pharmaceuticals. DOI: 10.1183/09031936.00119907
G. Ruberto. The author’s study was funded by AstraZeneca Canada Inc. DOI: 10.1183/09031936.00166606
M. Rumelhard. PM2.5 and PM organic extracts in the author’s study were supplied and chemically analysed by Renault (DIMAT). DOI: 10.1183/09031936.00085907
Y.J. Ryu. In addition to the Korea Health 21 Research and Development Project, the author’s study was also supported by a Samsung Biomedical Research Institute (Seoul, Korea) grant, number SBRI C-A6-402-1. DOI: 10.1183/09031936.00039507
S
Back to Top
D. Schaafsma. The author’s study was supported by a grant from Boehringer Ingelheim. DOI: 10.1183/09031936.00004907
C. Schindler. The author’s study was supported financially by a grant from Boehringer-Ingelheim GmbH, Basel, Switzerland. DOI: 10.1183/09031936.00015307
B. Schwierin is an employee of Actelion. DOI: 10.1183/09031936.00138706
K. Scrine has been an employee of Boehringer-Ingelheim since 1976. The author’s study was funded by Boehringer-Ingelheim Ltd. DOI: 10.1183/09031936.00023907
M.R. Sears holds the AstraZeneca Chair in Respiratory Epidemiology at McMaster University. DOI: 10.1183/09031936.00080007
E.S. Segal. The author is employed by Actelion Pharmaceuticals Ltd as VP and Head of Global Drug Safety. The author has also acted as an expert on the subject of the manuscript in presentations to the Drug Information Association and the EMEA. DOI: 10.1183/09031936.00138706
S. Senini. Pfizer contributed some unencumbered funding to reduce some of the costs of the author’s study. Pfizer supplied azithromycin for the author’s study. Funding sources did not participate in the design or conduct of this study, data analysis, manuscript preparation or review. DOI: 10.1183/09031936.00163306
D. Serisier. Pfizer contributed some unencumbered funding to reduce some of the costs of the author’s study. Pfizer supplied azithromycin for the author’s study. Funding sources did not participate in the design or conduct of this study, data analysis, manuscript preparation or review. DOI: 10.1183/09031936.00163306
H.J. Seyfarth has received speaker's honoraria from Actelion Pharmaceuticals and Schering. DOI: 10.1183/09031936.00032407
F. Sheikh. Funding support for the research described in the author’s study was obtained from the Philip Morris External Research Program. DOI: 10.1183/09031936.00141805
E.K. Silverman has received grant support, consulting fees and honoraria from GlaxoSmithKline for studies of COPD genetics. The author has also received a speaker fee from Wyeth for a talk on COPD genetics and honoraria from Bayer. DOI: 10.1183/09031936.00009307
A. Spanevello's attendance to the 2006 ERS Congress was funded by Pfizer. He also received funds as a member of staff, fees for speaking and funds for research. DOI: 10.1183/09031936.00112306
M.R. Stämpfli. The author’s study was supported by a grant-in-aid provided by AstraZeneca International. DOI: 10.1183/09031936.00025907
N.L. Stephens has received one operating grant from the External Research Fund of the Philip Morris Company. Funding support for the research described in the author’s study was obtained from the Philip Morris External Research Program. DOI: 10.1183/09031936.00141805
P.J. Sterk has received honoraria and travel grants for speaking at meetings, not exceeding US$1,500 per year during the past 5 years. In addition, P.J. Sterk receives a honorarium as Chief Editor of the European Respiratory Journal. Medication for the author’s study was donated by GlaxoSmithKline. Representatives of the company reviewed and commented on the protocol but made no other contributions to its design, conduct, interpretation or presentation. DOI: 10.1183/09031936.00111806
S. Stewart has previously acted as a research and educational consultant for Actelion Pharmaceuticals Ltd (Australia). The author’s study was partially supported by an unrestricted research grant from Actelion Pharmaceuticals Ltd. DOI: 10.1183/09031936.00092306
D. Stolz. The author’s study was supported financially by a grant from Boehringer-Ingelheim GmbH, Basel, Switzerland. DOI: 10.1183/09031936.00015307
G.Y. Suh. In addition to the Korea Health 21 Research and Development Project, the author’s study was also supported by a Samsung Biomedical Research Institute (Seoul, Korea) grant, number SBRI C-A6-402-1. DOI: 10.1183/09031936.00039507
J. Sültz has been paid by the Bavarian statutory accident insurance institutions for the agricultural sector for the time spent on the educational programme for the farmers involved in the author’s study. DOI: 10.1183/09031936.00023807
C. Surber. The author’s study was supported financially by a grant from Boehringer-Ingelheim GmbH, Basel, Switzerland. DOI: 10.1183/09031936.00015307
T
Back to Top
C. Talamo. The PLATINO study was funded by Boehringer Ingelheim GmbH (Ingelheim, Germany). The funding source had no influence on the analyses or interpretation of the results presented in the paper. The corresponding author (A.M.B. Menezes) had full access to all the data in the study and had final responsibility for the decision to submit for publication. DOI: 10.1183/09031936.00083507
M. Tamm. The author’s study was supported financially by a grant from Boehringer-Ingelheim GmbH, Basel, Switzerland. DOI: 10.1183/09031936.00015307
V.F. Tapson has received research grants, and lecture and consulting fees from Sanofi Aventis. The author has also received consulting fees from Bayer and Eisai. V.F. Tapson does not own stock in any pharmaceutical or biotechnology company. DOI: 10.1183/09031936.00098007
H.A.W.M. Tiddens has received, within the last 3 years, honoraria and travel expenses for lectures and workshops from Hoffman-La-Roche and Genentech. The Erasmus MC, Sophia Children’s Hospital (the cystic fibrosis centre used in the author’s study) has received, in the last 5 years, research grants from Hoffman-La-Roche. The author’s study was supported by Roche (the Netherlands), support with nebulisers was provided by Romedic (Meerssen, the Netherland) and support with pulsoxymeters was provided by MTT (Wageningen, the Netherlands). DOI: 10.1183/09031936.00031107
C. Tiplady. The author’s study was supported by a research grant from LEO Pharma to pH Associates to conduct the project. pH Associates were involved in the design of the author’s study and provided assistance with data collation and reporting. DOI: 10.1183/09031936.00140506
M. Travaci. The author’s study was supported by a research grant from Merck Sharpe and Dohme. DOI: 10.1183/09031936.00063106
A. Tremblay has received speaker's honoraria for medical presentations on malignant pleural effusions/Pleurx catheter. DOI: 10.1183/09031936.00164706
J. Trujillo-Santos. The RIETE Registry was supported by an unrestricted educational grant from Sanofi-Aventis Spain. The Registry Coordinating Center, S&H Medical Science Service, provided logistic and administrative support. DOI: 10.1183/09031936.00071007
U
Back to Top
V
Back to Top
G. Valdivia. The PLATINO study was funded by Boehringer Ingelheim GmbH (Ingelheim, Germany). The funding source had no influence on the analyses or interpretation of the results presented in the paper. The corresponding author (A.M.B. Menezes) had full access to all the data in the study and had final responsibility for the decision to submit for publication. DOI: 10.1183/09031936.00083507
C.K. van der Ent. The author has received unrestricted grants, amounting to €200,000 from GlaxoSmithKline, €50,000 from Grünenthal and €20,000 from Roche Pharmaceuticals. DOI: 10.1183/09031936.00051406
L.J. van der Giessen has received, within the last 4 years, travel expenses for conferences from Roche. The Erasmus MC, Sophia Children’s Hospital (the cystic fibrosis centre used in the author’s study) has received, in the last 5 years, research grants from Hoffman-La-Roche. The author’s study was supported by Roche (the Netherlands), support with nebulisers was provided by Romedic (Meerssen, the Netherland) and support with pulsoxymeters was provided by MTT (Wageningen, the Netherlands). DOI: 10.1183/09031936.00031107
T.H. van Kuppevelt. An unrestricted educational grant for the author’s study was received from GlaxoSmithKline (Zeist, The Netherlands). DOI: 10.1183/09031936.00125106
D. Vethanayagam has received financial support (consulting and lecture fees) in the past 5 years from AstraZeneca, GlaxoSmithKline, Novartis and Nycomed. DOI: 10.1183/09031936.00119907
C.G. Victora. The PLATINO study was funded by Boehringer Ingelheim GmbH (Ingelheim, Germany). The funding source had no influence on the analyses or interpretation of the results presented in the paper. The corresponding author (A.M.B. Menezes) had full access to all the data in the study and had final responsibility for the decision to submit for publication. DOI: 10.1183/09031936.00083507
K. Viel is an employee of Boehringer-Ingelheim, the manufacturer of Tiotropium (Spiriva®), and has received reimbursements for attending symposia. The author’s study was funded by Boehringer-Ingelheim Ltd. DOI: 10.1183/09031936.00023907
A.M. Vignola†. The author’s study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
W
Back to Top
C. Wainwright. Pfizer contributed some unencumbered funding to reduce some of the costs of the author’s study. Pfizer supplied azithromycin for the author’s study. Funding sources did not participate in the design or conduct of this study, data analysis, manuscript preparation or review. DOI: 10.1183/09031936.00163306
K. Walmsley. Pfizer contributed some unencumbered funding to reduce some of the costs of the author’s study. Pfizer supplied azithromycin for the author’s study. Funding sources did not participate in the design or conduct of this study, data analysis, manuscript preparation or review. DOI: 10.1183/09031936.00163306
A-B. Wanzenried. The author’s study was supported financially by a grant from Boehringer-Ingelheim GmbH, Basel, Switzerland. DOI: 10.1183/09031936.00015307
J.A. Wedzicha has received research funding for the published study and honoraria for speaking at meetings from Boehringer-Ingelheim and Pfizer. The author also received reimbursements for attending symposia. The author’s study was funded by Boehringer-Ingelheim Ltd. DOI: 10.1183/09031936.00023907
D. White. The author is a consultant for Respironics Inc, Alfred E. Mann Foundation, Aspire Medical, Itamar Medical, PAVAD and WideMed. The author occasionally consults for Cephalon, and Organon, and has research grants from Respironics Inc, Alfred E. Mann Foundation , Cephalon and WideMed. DOI: 10.1183/09031936.00063406
T.M.A. Wilkinson has received sponsorship from Boehringer-Ingelheim for travel to academic meetings. The author’s study was funded by Boehringer-Ingelheim Ltd. DOI: 10.1183/09031936.00023907
J. Wimperis has received financial support from LEO Pharma to attend several conferences. The author’s study was supported by a research grant from LEO Pharma to pH Associates to conduct the project. pH Associates were involved in the design of the author’s study and provided assistance with data collation and reporting. DOI: 10.1183/09031936.00140506
H. Wirtz has received speaker's honoraria from Actelion Pharmaceuticals and Schering. DOI: 10.1183/09031936.00032407
P. Wrighton-Smith. The author is an employee of, and shareholder in, Oxford Immunotec. DOI: 10.1183/09031936.00145906
X
Back to Top
Y
Back to Top
Z
Back to Top
J. Zaagsma has received an unrestricted educational grant from Boehringer Ingelheim. The author’s study was supported by a grant from Boehringer Ingelheim. DOI: 10.1183/09031936.00004907
H. Zackon. The author’s study was funded by AstraZeneca Canada Inc. DOI: 10.1183/09031936.00166606
J. Zhu. The author’s study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
S. Zielen has, within the last 3 years, received honoraria for lectures and attendance at Paediatric Advisory Boards from Merck Sharpe and Dohme. The author’s study was supported by a research grant from Merck Sharpe and Dohme. DOI: 10.1183/09031936.00063106
A.B. Zuidhof. The author’s study was supported by a grant from Boehringer Ingelheim. DOI: 10.1183/09031936.00004907
Back to Top
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |